Exploratory/Developmental Grants Related to the World Trade Center Health Program (R21)
Supports early-stage exploratory/developmental research on diagnostic or treatment uncertainty for World Trade Center Health Program enrollees, aimed at improving treatment effectiveness and diagnostic practices.
⚑ Foreign institutions, foreign components, and non-domestic components of U.S. organizations are not allowed. · R21 exploratory/developmental mechanism; minimal or no preliminary data expected. · Project focus is limited to WTC Health Program participants under Subtitle C of the James Zadroga 9/11 Health and Compensation Act. · Award ceiling: $365,000.
This is a biomedical/clinical World Trade Center Health Program R21 focused on diagnostic and treatment uncertainty, which is far outside IPPRA’s core survey, risk-perception, energy, weather, and policy-evaluation lines. The team might understand public health risk communication in the abstract, but this is not plausibly their PI-level research program.
JUDGED AGAINST THE ROSTER'S PUBLICATION DOSSIER · GPT-5.4-MINI · 2026-10-08
Unit fits — one characterization, each unit's own rules
| IPPRA | 58 good | portfolio topic: public_health (primary); social/behavioral work is minor; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Physical Sciences & Engineering (demo) | 55 good | technical depth: minor; funds applied research |
| Tom Love Innovation Hub | 30 weak | funds applied research; deep-tech content |
Description
The World Trade Center (WTC) Health Program supports exploratory and developmental research projects (R21) that address issues related to diagnostic or treatment uncertainty among individuals receiving monitoring and/or treatment under Subtitle C of the James Zadroga 9/11 Health and Compensation Act of 2010, as amended. This R21 Notice of Funding Opportunity (NOFO) is intended to encourage exploratory/developmental research by supporting the early and conceptual stages of project development to assess the feasibility of new areas of investigation with the potential to improve treatment effectiveness and diagnostic practices. These studies may lead to breakthroughs in a particular area or to the development of new interventions, techniques, agents, methodologies, models, or approaches with potential clinical impact. They are expected to break new ground or extend prior discoveries in new directions or applications. Applicants are expected to propose research for which there is likely to be minimal or no preliminary data.
Eligibility
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the HHS Grants Policy Statement, are not allowed.
Apply
View on Grants.gov → CONTACT: Centers for Disease Control and Prevention - ERA <jcy5@cdc.gov>
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · HHS services agencies (SAMHSA / HRSA / CDC / ACF) conventions SEE AN HHS EXAMPLE →
Funder-faithful document skeletons — HHS services agencies (SAMHSA / HRSA / CDC / ACF)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.